Greg Mayes, Antios Therapeutics CEO

An­tios' HBV col­lab axed af­ter clin­i­cal hold, but biotech be­lieves safe­ty in­ci­dent is not treat­ment-re­lat­ed

The FDA has placed a clin­i­cal hold on a Phase IIa study of An­tios Ther­a­peu­tics’ in­ves­ti­ga­tion­al he­pati­tis B med, CEO Greg Mayes con­firmed to End­points News in an emailed state­ment.

A safe­ty re­port was de­liv­ered to the biotech on May 17 af­ter a pa­tient dosed in a triple com­bi­na­tion co­hort of the study had ex­pe­ri­enced brady­car­dia and hy­poten­sion. The triple com­bo in­clud­ed An­tios’ ATI-2173, As­sem­bly Bio­sciences’ ve­bi­corvir and Viread, an ap­proved an­tivi­ral for HIV and he­pati­tis B.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.